Margalit Corber v. Xanodyne Pharmaceuticals, Inc.

771 F.3d 1218, 2014 WL 6436154
Court of Appeals for the Ninth Circuit·Decided November 18, 2014·No. 13-56306, 13-56310·Published·Cited by 24 cases

Opinions

Opinion by Judge GOULD; Dissent by Judge RAWLINSON.

OPINION

GOULD, Circuit Judge:

We must decide whether removal is proper under the “mass action” provision of the Class Action Fairness Act of 2005 (“CAFA”), 28 U.S.C. § 1332(d)(ll)(B)(i), when plaintiffs in several actions1 moved for coordination in the state trial court pursuant to California Code of Civil Procedure section 404 “for all purposes” and justified .their request in part by asserting a need to avoid inconsistent judgments. CAFA extends federal removal jurisdiction for certain class actions and for mass actions in which “monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” 28 U.S.C. § 1332(d)(ll)(B)(i). Because we conclude that all of the CAFA requirements for a removable mass action are met under the totality of the circumstances in these cases, we reverse the district court’s remand orders.

[1221] I

Defendants-Appellants Teva Pharmaceuticals USA, Inc. (“Teva”) and Xanodyne Pharmaceuticals, Inc. (“Xanodyne”) appeal from the district court’s orders remanding these cases to state court. These cases were two of twenty-six pending before the district court alleging injuries related to the ingestion of propoxyphene, an ingredient found in the Darvocet and Darvon pain relief drugs, as well as in generic pain relievers. There are additional propoxy-phene cases pending in multidistrict litigation in the Eastern District of Kentucky. See In re: Darvocet, Darvon & Propoxyphene Prods. Liab. Litig., 780 F.Supp.2d 1379 (J.P.M.L.2011). .

Propoxyphene is a pain reliever that was used in the United States to treat mild to moderate pain from 1957 through November 2010, when drugs containing propoxy-phene were taken off the market because of safety concerns. Teva held the rights to the generic form of Darvocet and Darvon, and Plaintiffs allege that Teva was involved in all aspects of the creation, distribution, and sale of generic propoxy-phene products. Xanodyne acquired the rights to Darvocet and Darvon in 2007.

To date, more than forty actions have been filed in California state courts regarding propoxyphene pain relievers. On October 23, 2012, a group of attorneys responsible for many of the propoxyphene actions against Teva, Xanodyne, and other defendants filed petitions asking the California Judicial Council to establish a coordinated proceeding for all California pro-poxyphene actions under section 404 of the California Code of Civil Procedure.2 California Code of Civil Procedure section 404.1, which sets out the standards for coordination, states:

Coordination of civil actions sharing a common question of fact or law is appropriate if one judge hearing all of the actions for all purposes in a selected site or sites will promote the ends of justice taking into account whether the common question of fact or law is predominating and significant to the litigation; the convenience of parties, witnesses, and counsel; the relative development of the actions and the work product of counsel; the efficient utilization of judicial facilities and manpower; the calendar of the courts; the disadvantages of duplicative and inconsistent rulings, orders, or judgments; and, the likelihood of settlement of the actions without further litigation should coordination be denied.

Plaintiffs asked for coordination of their lawsuits for reasons consistent with the above factors, including concerns that there could be potential “duplicate and inconsistent rulings, orders, or judgments,” and that without coordination, “two or more separate courts ... may render different rulings on liability and other issues.” Plaintiffs argued in their petitions and the supporting memoranda that the cases should be coordinated before one judge “hearing all of the actions for all purposes,” to address “the same or substantially similar” causes of action, is[1222] sues of law, and issues of material fact. After these petitions for coordination were filed, Teva and Xanodyne removed the cases to federal district court under CAFA’s mass action provision.

CAFA provides federal district courts with original jurisdiction over “mass actions” if the actions meet all of the statutory requirements. 28 U.S.C. § 1332(d). CAFA defines a mass action as:

[A]ny civil action ... in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact, except that jurisdiction shall exist only over those plaintiffs whose' claims in a mass action satisfy the jurisdictional amount requirements under subsection (a).

28 U.S.C. § 1332(d)(11)(B)(i). The parties dispute only whether Plaintiffs’ petitions for coordination constitute proposals for the cases “to be tried jointly” under CAFA.

The district court held that it lacked jurisdiction under CAFA because Plaintiffs’ petitions for coordination were not proposals to try the cases jointly, and it remanded the cases back to state court. The district court distinguished these cases from the Seventh Circuit’s decision in In re Abbott Laboratories, Inc., 698 F.3d 568 (7th Cir.2012), and held that Plaintiffs’ petitions were sufficiently different from Abbott’s consolidation request because the petitions filed in this case focused on pre-trial purposes, while the petition filed in Abbott explicitly sought consolidation “through trial.”

Defendants sought permission to appeal the district court’s remand orders, which we granted. A three-judge panel affirmed. See Romo v. Teva Pharm. USA, Inc., 731 F.3d 918 (9th Cir.2013), cert. denied, - U.S. -, 134 S.Ct. 2872, 189 L.Ed.2d 833 (2014). A majority of nonre-eused judges voted to rehear the case en banc. 742 F.3d 909 (9th Cir.2014) (order). We review the district court’s remand order de novo. See Abrego Abrego v. Dow Chem. Co., 443 F.3d 676, 679 (9th Cir.2006) (per curiam).

II

Free access — add to your briefcase to read the full text and ask questions with AI

Margalit Corber v. Xanodyne Pharmaceuticals, Inc., 771 F.3d 1218, 2014 WL 6436154 (9th Cir. 2014).

771 F.3d 1218 (Margalit Corber v. Xanodyne Pharmaceuticals, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related